In partnership with Promega, Abzena’s experts Grant Harradence and Robert Francis PhD FRMS will be taking part in a webinar hosted by them entitled ‘Always Look on the Bright Side of (Cell) Death: Cytotoxicity Assays for Antibody Drug Conjugate Development’ on the 20th November at 3:00pm GMT.

Time: 9:00am CST | 10:00am EST | 3:00pm GMT

Register Here

In this November webinar, Darren Heywood from Promega will introduce plate-based cell health assays for drug development and screening in 3D cell cultures. Grant Harradence and Robert Francis join Darren and will discuss how Abzena applies developability principles throughout the discovery and development process, using two approved antibody-drug conjugates (ADCs) to demonstrate the robustness of bioassays in 3D cell culture models.

Additionally, they will highlight a range of biological methods that help researchers select lead ADCs for further discovery, and how plate-based assays integrate with comprehensive bioassay assessments, including real-time imaging and microscopy techniques.

In this webinar, you will learn:

• The benefits of drug screening in 3D cell cultures and how using optimized 3D cell-based assays address the challenges of measuring cell health in 3D cultures, leading to more effective assessment of key outcomes, such as viability and apoptosis
• The role of bioassays in ADC developability and lead selection
• How complex co-culture and 3D in vitro models enable researchers to select the best candidate to take forward for clinical development

Register Here

Our Speakers

About Grant Harradence
Grant is an experienced scientific professional with over 20 years of experience in the biotechnology sector. As a Senior Scientist and First Line Manager at Abzena he has extensive experience in cell-based and biochemical assay development – utilized to deliver technical programs in a timely manner.

About Robert Francis PhD
Robert is a Fellow of the Royal Microscopical Society (FRMS) and leads a bioassay team of scientists for live and fixed cell imaging within Abzena fulfilling contract research, including development of novel imaging based assays. Robert and his team play a key role in translating a scientific vision to practical step-by-step experimentation through scientific collaboration and consultation. Robert has over a decade of imaging experience and is based at our Cambridge, UK facility which specializes in early discovery services ahead of candidate selection for both complex biologics and bioconjugates.

Register Here